➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
AstraZeneca
Harvard Business School
Mallinckrodt

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

FENSOLVI KIT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Fensolvi Kit patents expire, and when can generic versions of Fensolvi Kit launch?

Fensolvi Kit is a drug marketed by Tolmar and is included in one NDA. There is one patent protecting this drug.

This drug has sixty-eight patent family members in twenty-six countries.

The generic ingredient in FENSOLVI KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

Summary for FENSOLVI KIT
International Patents:68
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
DailyMed Link:FENSOLVI KIT at DailyMed
Drug patent expirations by year for FENSOLVI KIT

US Patents and Regulatory Information for FENSOLVI KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FENSOLVI KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 ⤷  Free Forever Trial ⤷  Free Forever Trial
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for FENSOLVI KIT

Country Patent Number Estimated Expiration
Germany 60111068 ⤷  Free Forever Trial
Australia 2006241376 ⤷  Free Forever Trial
Denmark 1126822 ⤷  Free Forever Trial
Japan 2013253101 ⤷  Free Forever Trial
Cyprus 1113920 ⤷  Free Forever Trial
China 101669900 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 0024374 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
McKesson
AstraZeneca
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.